Helicos BioSciences Corporation

Helicos BioSciences Awarded ‘Revolutionary Genome Sequencing Technologies – The $1000 Genome’ Grant

Helicos BioSciences Awarded ‘Revolutionary Genome Sequencing Technologies – The $1000 Genome’ Grant

October 4, 2006

Recognition by National Human Genome Institute to Accelerate Research of Helicos Single Molecule Sequencing Technology

Helicos BioSciences Corporation

Helicos BioSciences Names Louise Mawhinney Vice President & Chief Financial Officer

Helicos BioSciences Names Louise Mawhinney Vice President & Chief Financial Officer

October 12, 2006

CAMBRIDGE, Mass.— October 12, 2006 --Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, announced today that it has named longtime financial executive Louise Mawhinney as Vice President and Chief Financial Officer.

Stanley N. Lapidus, President and CEO of Helicos, said, “We are pleased to have Louise join our executive team. Her operational expertise and deep experience with the financial markets is a great addition to my staff and provides a crucial skill set required for our continued evolution as a company.”

Morphotek, Inc.

Morphotek Raises $40 Million to Advance its Antibody Pipeline

Morphotek Raises $40 Million to Advance its Antibody Pipeline

October 12, 2006

Exton, PA, October 12, 2006 -- Morphotek® Inc., a privately held biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies, announced today the closing of a $40 million Series D financing. The financing was led by Investor Growth Capital of New York and included participation of new investors MDS Capital and Hunt BioVentures as well as existing investors Forward Ventures, Morgenthaler Ventures, SR One, Flagship Ventures, Burrill & Co., CB Health Ventures, and Rock Maple Ventures.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors

AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors

October 23, 2006

CAMBRIDGE, MA October 23, 2006 – AVEO Pharmaceuticals, Inc. (AVEO), a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that it has begun enrolling patients in a Phase I clinical study for AV-412, a next generation oral tyrosine kinase inhibitor of EGFR/HER2. The open-label, sequential dose escalation study will be conducted at several leading cancer institutions to examine the safety, tolerability and optimal dosing of AV-412.

Adnexus Therapeutics

Adnexus Therapeutics Announces Issuance of U.S. Patent for Broad Protection of New Therapeutic Class, Adnectins(TM)

Adnexus Therapeutics Announces Issuance of U.S. Patent for Broad Protection of New Therapeutic Class, Adnectins(TM)

October 23, 2006

Waltham, MA, October 23, 2006 – Adnexus TherapeuticsTM, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 7,115,396 with broad composition of matter claims to AdnectinTM proteins. Exclusively owned by Adnexus, this patent further expands the company’s ownership of Adnectins, a class of targeted biologics with broad applicability across many aspects of the biotechnology industry, including both therapeutics and diagnostics.

Harry Wilcox Joins Flagship Ventures as CFO and Partner

Harry Wilcox Joins Flagship Ventures as CFO and Partner

October 23, 2006

Harry Wilcox has joined Flagship Ventures as CFO and Partner. Harry will take over from Cheryl Goyette who will be leaving us during November to join a newly formed venture firm as their CFO. We are thankful for the many contributions made by Cheryl in managing our partnership finance activities over the last 8 years and look forward to continuing to excel in this area under the able leadership of Harry.

Ensemble Therapeutics Corporation

The Leukemia & Lymphoma Society and Ensemble Discovery Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers

The Leukemia & Lymphoma Society and Ensemble Discovery Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers

November 13, 2006

First initiative under the Society’s new Therapy Acceleration Program, designed to move new therapies more quickly into the development pipeline

Mascoma Corporation

Mascoma Corporation Raises $30 Million in Series B Funding Led By General Catalyst Partners

Mascoma Corporation Raises $30 Million in Series B Funding Led By General Catalyst Partners

November 13, 2006

Leader in cellulosic biomass-to-ethanol development and production to continue research and development to make renewable fuel a sustainable reality for consumers

Flagship’s David Berry quoted in eBioNews in an article titled, “A New Bloom for Algae.”

Flagship’s David Berry quoted in eBioNews in an article titled, “A New Bloom for Algae.”

July 8, 2010

David Berry was recently interviewed for an article in eBioNews outlining efforts over the last several years to utilize algae as a source for biofuels.

A New Bloom for Algae

Thursday, 08 July 2010 07:49

A DOE roadmap marks a return to research on a source of fuel that was once thought too costly.

Accuri Cytometers, Inc.

Accuri Cytometers Completes $6 Million Series E Financing

Accuri Cytometers Completes $6 Million Series E Financing

July 12, 2010

ANN ARBOR, Mich., July 12 /PRNewswire/ -- Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.